Physician profile
Evyatar Evron
NPI 1922596501
$2,840.72
in general payments reported to CMS, 2019-2025
22 companies · $857 in 2025
The $857 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $510 · 2023: $928 · 2024: $545 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,227 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,227.29 |
| Education | $103.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $999.64 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $293.05 | 2022-2025 | |
| Genzyme Corporation | $232.78 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $222.35 | 2022-2024 | Dupixent |
| Janssen Biotech, INC. | $197.06 | 2022-2023 | Tremfya, Remicade, Simponi Aria |
| Amgen INC. | $141.45 | 2023-2025 | Otezla, Otezla |
| Pfizer INC. | $125.00 | 2023 | |
| Arcutis Biotherapeutics, INC. | $85.49 | 2025 | Zoryve |
| Lilly USA, LLC | $80.33 | 2022-2024 | Taltz, Ebglyss |
| Botanix Sb INC | $74.26 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.37 | 2023-2024 | Spevigo |
| Galderma Laboratories, L.P. | $51.94 | 2023-2025 | Nemluvio |
| Incyte Corporation | $40.00 | 2022-2023 | Opzelura |
| Convatec INC. | $36.36 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $30.39 | 2022-2025 | Valchlor |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $30.06 | 2022 | |
| Musculoskeletal Transplant Foundation INC. | $29.43 | 2023 | |
| Ucb, INC. | $27.20 | 2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $25.72 | 2025 | |
| Leo Pharma INC. | $24.04 | 2025 | Adbry |
| Paratek Pharmaceuticals, INC. | $21.05 | 2022 | |
| Biofrontera INC. | $19.75 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evyatar Evron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.